Neuroendocrine tumors (NET) are a rare kind neoplasm that arises from cells of the endocrine (hormonal) and nervous systems. These tumors commonly occur in the intestine, where they are often called carcinoid tumors; however, they can also be found in the pancreas, lungs, and the rest of the body.
In the year 2017, the total number of the prevalent cases of Neuroendocrine tumors in the 7 MM was estimated to be 454,000 cases.
The newsletter by DelveInsight offers a brief overview of the indication, its subtypes, and symptoms. It also brings into focus the epidemiological trends segmented into geographies in the 7MM, ethnicity, gender, total, and diagnosed cases.
As per DelveInsight assessments, the market size of Neuroendocrine tumors is anticipated to increase for the study period, 2017–2030. The newsletter aims to help its clients and readers to gain insights into market trends and the pipeline therapies that shall veer the NET market in a positive direction.
For rich insights into Neuroendocrine tumors market landscape, fill the form and get the newsletter right into your inbox.
Escape the hassle of filling the forms every time by subscribing to our emailer's list and get all the updates and trends in the pharma industry into your inbox.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Collaborations and deals in the domain
- R&D in the field
- Top conferences
- Support from International organizations